Literature DB >> 16868443

HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients.

Roberto Littera1, Carlo Carcassi, Alessandro Masala, Paola Piano, Paolo Serra, Francesco Ortu, Nicoletta Corso, Basilia Casula, Giorgio La Nasa, Licinio Contu, Paolo Emilio Manconi.   

Abstract

BACKGROUND: Hypersensitivity reaction to nevirapine, which in some cases can be fatal, shows a higher prevalence in Sardinia in comparison with other Italian regions.
OBJECTIVE: This study demonstrates that hypersensitive reaction to nevirapine in Sardinian HIV-infected patients is associated with the HLA Cw8-B14 haplotype. These two HLA class I antigens are in strong linkage disequilibrium in the Sardinian population.
METHODS: Forty-nine Sardinian HIV-positive patients treated with nevirapine were studied. Thirteen (26%), developed a hypersensitive reaction thus requiring the drug to be discontinued. HLA class I and II molecular typing was performed in both nevirapine-hypersensitive and nevirapine-tolerant patients. To avoid biased representation of the allele frequencies in the two groups of treated patients, molecular typing was also performed in 82 HIV-positive patients who had not been treated with nevirapine.
RESULTS: Considerable overlap was observed for the clinical, immunological and demographic characteristics of the 13 hypersensitive patients and 36 tolerant patients. Clinical parameters included viral load, status of HIV infection, CD4 and CD8 cell counts, hepatitis C virus/hepatitis B virus co-infections. Forty-six percent (6/13) of the nevirapine-hypersensitive subjects had the HLA-Cw8 and HLA-B14(65) antigens compared with 5% (2/36) of the nevirapine-tolerant group (P = 0.004; Pc = 0.05).
CONCLUSION: In agreement with other recent reports, the utility of HLA typing in HIV patients to identify genetic factors that may confer susceptibility to drug-induced hypersensitive reaction was confirmed. A careful choice of antiretroviral therapy in susceptible individuals should significantly reduce the risk of severe hypersensitive reaction.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16868443     DOI: 10.1097/01.aids.0000238408.82947.09

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  47 in total

1.  Can antiretroviral therapy be tailored to each human immunodeficiency virus-infected individual? Role of pharmacogenomics.

Authors:  Victor Asensi; Julio Collazos; Eulalia Valle-Garay
Journal:  World J Virol       Date:  2015-08-12

Review 2.  Antimicrobial stewardship's new weapon? A review of antibiotic allergy and pathways to 'de-labeling'.

Authors:  Jason Trubiano; Elizabeth Phillips
Journal:  Curr Opin Infect Dis       Date:  2013-12       Impact factor: 4.915

3.  Clinical perspectives on human genetic screening to prevent nevirapine toxicity.

Authors:  David W Haas; Piroon Mootsikapun; Kiat Ruxrungtham; Daniel Podzamczer
Journal:  Per Med       Date:  2012-09-01       Impact factor: 2.512

Review 4.  Pharmacogenomics of antimicrobial agents.

Authors:  Ar Kar Aung; David W Haas; Todd Hulgan; Elizabeth J Phillips
Journal:  Pharmacogenomics       Date:  2014       Impact factor: 2.533

Review 5.  Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity.

Authors:  Volker M Lauschke; Yitian Zhou; Magnus Ingelman-Sundberg
Journal:  Pharmacol Ther       Date:  2019-01-22       Impact factor: 12.310

Review 6.  Perspectives on pharmacogenomics of antiretroviral medications and HIV-associated comorbidities.

Authors:  David W Haas; Philip E Tarr
Journal:  Curr Opin HIV AIDS       Date:  2015-03       Impact factor: 4.283

Review 7.  Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy.

Authors:  Rebecca Pavlos; Simon Mallal; David Ostrov; Yuri Pompeu; Elizabeth Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2014 Jan-Feb

8.  Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa.

Authors:  Elizabeth Phillips; John A Bartlett; Ian Sanne; Michael M Lederman; John Hinkle; Franck Rousseau; David Dunn; Rebecca Pavlos; Ian James; Simon A Mallal; David W Haas
Journal:  J Acquir Immune Defic Syndr       Date:  2013-02-01       Impact factor: 3.731

Review 9.  Successful translation of pharmacogenetics into the clinic: the abacavir example.

Authors:  Elizabeth Phillips; Simon Mallal
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

10.  HLA-Cw*04 allele associated with nevirapine-induced rash in HIV-infected Thai patients.

Authors:  Sirirat Likanonsakul; Tippawan Rattanatham; Siriluk Feangvad; Sumonmal Uttayamakul; Wisit Prasithsirikul; Preecha Tunthanathip; Emi E Nakayama; Tatsuo Shioda
Journal:  AIDS Res Ther       Date:  2009-10-21       Impact factor: 2.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.